A rumor that a new miracle drug that could allegedly extend the lives of dogs was in development circulated online in early April 2026.
Users on social media platform X (archived) shared the purported news, claiming the company behind the development aims to have the drug on the market by 2027.
🔥🚨BREAKING: Scientists have created a pill called LOT-002 that can extend the lifespan of dogs by many years, and their main priority is to get it on the market by 2027, the company creating this Pill is called "Loyal."
This beef-flavored pill will be given to your dog daily,… pic.twitter.com/VzA3XoQhrx— Dom Lucre | Breaker of Narratives (@dom_lucre) April 9, 2026
The claim that scientists are actively developing such a drug is true, but it's important to note that the drug has not yet been approved by the FDA or brought to market, nor has any evidence been published about its efficacy.
We reached out to Loyal, the company developing the drug, to ask about its projected release date and will update this article if we receive a response.
Loyal stated its intention in developing the drug was to address "metabolic dysfunction" in senior dogs, which they defined as "a set of interconnected processes that contribute to poor metabolic health," resulting in conditions such as hypoglycemia.
Put simply, the drug — dubbed LOY-002 — aims to be preventive and delay "the start of many diseases that reduce quality of life for senior dogs and giving dogs, and their human family, more enjoyable time together," according to the company.
As of this writing, Loyal is engaged in what they call their "final effectiveness study" before seeking FDA approval. So while it is true the drug is in development, it remains to be seen if it comes to market and accomplishes its stated purpose.
The FDA accepted the drug's Reasonable Expectation of Effectiveness in February 2025 and Target Animal Safety in January 2026, completing two of three conditions for Expanded Conditional Approval by the FDA.
Conditional approval would allow Loyal to sell the drug "before proving it meets the 'substantial evidence' standard of effectiveness for full approval," according to the FDA.
Loyal wrote in a blog post, "Acceptance of these submissions signals that the FDA finds our data support that the drug is likely to be effective and safe for its intended use to extend healthy lifespan in senior dogs."
Loyal called its study "a double-blinded, placebo-controlled study with 1,300 dogs enrolled across 70 veterinary clinics nationwide" that has shown "no clinically significant adverse events" at doses up to five times the intended amount.
Numerous media outlets have covered Loyal's potential advancement in veterinary medicine as far back as 2022, including The New York Times, The Wall Street Journal, Wired, Newsweek, The Guardian, Forbes, NBC News and CBS News.
Dr. Abraham Manimalethu, a veterinarian in Las Vegas, told Snopes the potential new drug is something he would consider, if brought to market, "to help increase a dog's longevity as they get into their middle ages of life" alongside "the importance of being at a healthy body condition score along with regular exercise whereby the amount of calories an animal takes in is very important, even at early ages of life."
While he was optimistic about the possibilities, Manimalethu said it would take a lot more data for a veterinarian to make an informed decision about using the drug with their patients, adding, "there is always a potential to have side effects that would make the drug only marginally more helpful or potentially more risky than being without it."